The Leukemia & Lymphoma Society was founded in 1949 by Rudolph and Antoinette de Villiers, who had recently lost their 16 year old son to leukemia. Since then, LLS has been driven by the de Villiers nearly boundless belief that leukemia and other blood cancers could be cured. From its inception, LLS been helping to shape the ever-shifting paradigm of cancer research and drug discovery. More recently, we have been laser-focused on driving research in areas of unmet medical need, while helping to bridge the gap from academic discovery to drug development.
We launched our Therapy Acceleration Program (TAP) in 2007, as a strategic initiative to forge partnerships with academic research institutions, and with biotechnology and pharmaceutical companies, to speed the development of blood cancer therapies and bring help and hope to patients as quickly as possible.
To showcase TAP and its critical role in finding treatments and cures for blood cancers, we produced a series of films featuring a cast of key LLS research staff and executives. In a series of vignettes, we hear from the TAP team as they explain how LLS is helping companies and research institutions with novel compounds, biologics or diagnostic devices overcome bottlenecks and advance these projects through the drug development pipeline.
As always, our goal is to bring us closer to cures, today.
You can view the main TAP video here.
If you regularly recycle your plastics, papers and glass, you know they can be re-used for new purposes. You might be unaware, however, that smart research scientists can also recycle drugs, re-purposing them to treat other diseases.
In a partnership with the University of Kansas and the National Institutes of Health, LLS is testing auranofin, an arthritis drug, to treat patients with relapsed chronic lymphocytic leukemia. The collaboration is part of an aggressive effort to get new treatments to patients faster. Because the drug in this project was already FDA approved, scientists were able to move from animal studies to a Phase I trial for blood cancer patients in just one year! Helen Anbinder beat her CLL into remission twice thanks to a treatment developed by an LLS-funded researcher who her family supported. When her leukemia recurred a few years later, another new medication was waiting in the wings. Helen again credited LLS. "Research was progressing so quickly that I was able to be treated with a new drug combination that wasn't even available two years earlier." Researcher collaborations, novel combinations and new uses for existing drugs all give hope to people like Helen. And forward-thinking people like you who invest in research give hope to all cancer patients. If you haven't made a donation, please consider one, not someday, but today. Gratefully, John E. WalterPresident & CEO PS. We would like to honor every patient living with a blood cancer with a donation. Please donate in honor of one now.
Aaron Jones was 7 when he was diagnosed with leukemia. He battled valiantly for three years but tragically lost his life to the disease on June 28, 2012.
During his cancer journey Aaron spent many of his days at Children’s Hospital in Pittsburgh. While there, he had the thrill of meeting several of his heroes from the Pittsburgh Steelers, including Troy Polamalu and Brett Keisel. Aaron got so sick so quickly that he never got the chance to attend a Steelers game, but in August the Steelers organization and The Leukemia & Lymphoma Society teamed up to invite his family – mom, dad and two brothers - to attend a game.
“It has been hard since we lost Aaron; Our house is so empty without his laughs,” his mother, Shelly Jackson said. “Thank you for remembering the families, too, whether they are still in treatment or cured or passed on to heaven. It meant a lot to us but I think I was the only one who cried at the Steeler game that night.”
Thank you for your generous support through GlobalGiving.